Publications
Detailed Information
Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Hwang, S. S. | - |
dc.contributor.author | Kim, H-R. | - |
dc.contributor.author | Kim, H. J. | - |
dc.contributor.author | Kim, M. J. | - |
dc.contributor.author | Yoo, C-G. | - |
dc.contributor.author | Han, S. K. | - |
dc.contributor.author | Yim, J-J. | - |
dc.contributor.author | Shim, Y-S. | - |
dc.contributor.author | Kim, Y. W. | - |
dc.contributor.author | Lee, S. M. | - |
dc.date.accessioned | 2012-05-23T07:45:27Z | - |
dc.date.available | 2012-05-23T07:45:27Z | - |
dc.date.issued | 2009-03 | - |
dc.identifier.citation | EUROPEAN RESPIRATORY JOURNAL; Vol.33 3; 581-585 | ko_KR |
dc.identifier.issn | 0903-1936 | - |
dc.identifier.uri | https://hdl.handle.net/10371/76347 | - |
dc.description.abstract | Recently, resistance to additional first-line and injectable drugs was reported to be an independent risk factor for adverse outcomes in multidrug-resistant (MDR) tuberculosis (TB) patients. The aim of the present study was to confirm these observations in MDR-TB patients without Hill infection. MDR-TB patients treated at a tertiary referral hospital in South Korea between January 1996 and December 2005 were included. The unadjusted and adjusted odds ratios of adverse treatment outcome were calculated for resistance to each drug and combination of drugs using simple or multiple logistic regressions. None of the resistance to additional first-line or injectable drugs was associated with higher odds for adverse treatment outcome in 155 MDR but nonextensively drug-resistant (non-XDR) TB patients. However, streptomycin resistance was associated with 12 times the odds for adverse treatment outcome in 42 extensively drug-resistant (XDR) TB patients. Neither combinations of first-line drugs nor those of injectable drugs were associated with increased odds for adverse treatment outcomes in non-XDR MDR-TB patients or XDR-TB patients. Only streptomycin resistance among the first-line or injectable drugs was associated with adverse treatment outcomes in extensively drug-resistant tuberculosis patients without HIV infection. | ko_KR |
dc.description.sponsorship | The present study was funded by
grant 04-2006-115-0 from the Seoul National University College of Medicine Research Fund (Seoul, Republic of Korea). | ko_KR |
dc.language.iso | en | ko_KR |
dc.publisher | EUROPEAN RESPIRATORY SOC JOURNALS LTD | ko_KR |
dc.subject | Extensive drug resistance | ko_KR |
dc.subject | streptomycin | ko_KR |
dc.subject | tuberculosis | ko_KR |
dc.subject | multidrug resistance | ko_KR |
dc.title | Impact of resistance to first-line and injectable drugs on treatment outcomes in MDR-TB | ko_KR |
dc.type | Article | ko_KR |
dc.identifier.doi | 10.1183/09031936.00099608 | - |
dc.citation.journaltitle | EUROPEAN RESPIRATORY JOURNAL | - |
dc.description.citedreference | Kim DH, 2008, AM J RESP CRIT CARE, V178, P1075, DOI 10.1164/rccm.200801-132OC | - |
dc.description.citedreference | Migliori GB, 2008, EUR RESPIR J, V31, P1155, DOI 10.1183/09031936.00028708 | - |
dc.description.citedreference | Blaas SH, 2008, BMC INFECT DIS, V8, DOI 10.1186/1471-2334-8-60 | - |
dc.description.citedreference | Yu MC, 2008, EMERG INFECT DIS, V14, P849 | - |
dc.description.citedreference | Jeon CY, 2008, CLIN INFECT DIS, V46, P42, DOI 10.1086/524017 | - |
dc.description.citedreference | Kim HR, 2007, CLIN INFECT DIS, V45, P1290, DOI 10.1086/522537 | - |
dc.description.citedreference | Migliori GB, 2007, EUR RESPIR J, V30, P623, DOI 10.1183/09031936.00077307 | - |
dc.description.citedreference | Hamilton CD, 2007, CLIN INFECT DIS, V45, P338, DOI 10.1086/519292 | - |
dc.description.citedreference | Gandhi NR, 2006, LANCET, V368, P1575, DOI 10.1016/S0140-6736(06)69573-1 | - |
dc.description.citedreference | Raviglione M, 2006, INT J TUBERC LUNG D, V10, P1185 | - |
dc.description.citedreference | Kim HJ, 2006, EUR RESPIR J, V28, P576, DOI 10.1183/09031936.06.00023006 | - |
dc.description.citedreference | *CDCP, 2006, MMWR-MORBID MORTAL W, V55, P301 | - |
dc.description.citedreference | *WHO, 2006, WKLY EPIDEMIOL REC, V81, P430 | - |
dc.description.citedreference | Laserson KF, 2005, INT J TUBERC LUNG D, V9, P640 | - |
dc.description.citedreference | Ho YII, 1997, J ANTIMICROB CHEMOTH, V40, P27 | - |
dc.description.citedreference | HEIFETS L, 1989, ANTIMICROB AGENTS CH, V33, P1298 | - |
dc.description.citedreference | WAYNE LG, 1974, AM REV RESPIR DIS, V109, P147 | - |
dc.description.tc | 7 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.